If You Invested in HEALTHCARE AI ACQUISITION CORP (HAIAF)

Healthcare AI Acquisition Corp. (traded under the symbol HAIAF) is a Cayman Islands exempted company that has been formed to pursue an initial business combination. According to its SEC filings, the company is organized as Healthcare AI Acquisition Corp. and has ordinary shares and warrants outstanding. Its securities have been quoted on the OTC Markets Group Pink Open Market, and it files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-41145.

The company describes itself in regulatory documents as seeking to complete an initial business combination, sometimes referred to as a business combination or proposed business combination. Healthcare AI Acquisition Corp. maintains a trust account in which proceeds from its initial public offering were deposited. Public shareholders hold Class A ordinary shares, while there is also a Class B ordinary share structure referenced in its proxy materials. Shareholders have the right, in connection with certain shareholder meetings, to redeem their public shares for a pro rata portion of the funds held in the trust account.

Corporate structure and jurisdiction

Healthcare AI Acquisition Corp. is incorporated in the Cayman Islands, as disclosed in multiple Form 8-K and proxy filings. Its SEC filings list a Cayman Islands company number and U.S. tax identification number, reflecting its status as a foreign private issuer for corporate law purposes while being subject to U.S. securities regulation for its registered securities.

Business combination timeline and extensions

The company’s Articles of Association set a deadline by which it must consummate a business combination. In its definitive proxy statement and subsequent Form 8-K filings, Healthcare AI Acquisition Corp. describes shareholder votes on proposals to extend this deadline. The company has sought and obtained the right, via special resolutions of shareholders, to extend the date by which it must complete a business combination on a month-to-month basis by depositing a fixed amount per non-redeemed public share into the trust account for each extension.

These extensions are referred to in filings as the Extension Proposal or Extension Amendment Proposal. The board of directors may approve additional extensions up to an extended termination date, subject to the terms approved by shareholders. If the company does not complete a business combination by the applicable termination date and does not obtain further extensions, its filings state that it would cease all operations except for the purpose of winding up and would redeem 100% of the outstanding public shares from the trust account.

Trust account and shareholder redemptions

Healthcare AI Acquisition Corp. provides detailed information in its proxy statements and Form 8-K filings about the trust account and redemption mechanics. Holders of Class A ordinary shares issued in the IPO, referred to as public shares, may elect to redeem their shares in connection with certain shareholder meetings. The redemption price per public share is calculated as the pro rata amount in the trust account, including interest not previously used to pay taxes, divided by the number of outstanding public shares.

The company’s filings describe prior redemption events where a substantial number of public shares were redeemed, and corresponding amounts were removed from the trust account to pay redeeming shareholders. Following such redemptions, the filings specify the number of remaining Class A shares and the amount remaining in the trust account. The documents also note that the market price of the public shares on the OTC Pink Open Market may differ from the redemption price and that trading liquidity may be limited.

Sponsor arrangements and capital structure

Healthcare AI Acquisition Corp. has a sponsor entity, identified in its proxy statement as Atticus Ale LLC, which assumed sponsorship from an initial sponsor through a share transfer referred to as the Sponsor Handover. The filings describe founder shares (Class B ordinary shares) held by the sponsor and other initial shareholders, and the ability to convert these founder shares into Class A ordinary shares on a one-for-one basis prior to the closing of a business combination.

The company’s disclosures also describe agreements regarding private placement warrants purchased at the time of the IPO and arrangements under which a portion of those warrants may be surrendered for cancellation in exchange for Class A ordinary shares at the time of the initial business combination. These features are part of the capital structure that supports the company’s efforts to complete a business combination.

Proposed business combination

In its filings, Healthcare AI Acquisition Corp. states that it has identified a potential business combination target, referred to as the Target, and a proposed business combination. The company has entered into a business combination agreement with entities identified as Leading Partners Limited and Leading Group Limited, both Cayman Islands companies, for purposes of completing a business combination. The proxy statement and subsequent Form 8-K filings describe changes to the outside date by which this proposed business combination must be completed and the related extension mechanics.

Shareholders are informed that they are not being asked to vote on the business combination itself in the extension-related proxy materials. Instead, the purpose of the extension proposals is to provide additional time for Healthcare AI Acquisition Corp. to seek to consummate the proposed business combination.

Regulatory reporting and late filing notice

Healthcare AI Acquisition Corp. files periodic reports with the SEC and, when necessary, submits notifications of late filing. In a Form 12b-25 (NT 10-Q), the company reported that it was unable to file its Quarterly Report on Form 10-Q for a specified fiscal quarter by the prescribed due date due to difficulty in completing and obtaining required financial and other information without unreasonable effort and expense. In that notification, the company indicated that it expected to file the report within the extension period allowed under SEC rules and stated that it did not anticipate a significant change in results of operations compared to the corresponding period of the prior year.

Shareholder meetings and governance

The company’s definitive proxy statement invites shareholders to an annual general meeting and outlines the matters to be voted upon, including the extension proposal, ratification of the independent registered public accounting firm, and a potential adjournment proposal. The filings describe the voting thresholds required under Cayman Islands law for special and ordinary resolutions, and they provide the results of shareholder votes in subsequent Form 8-K filings.

Healthcare AI Acquisition Corp. emphasizes in its proxy materials that if the extension proposal and related contributions to the trust account are not approved, and if a business combination is not completed by the existing termination date, the company would be required to dissolve and redeem the public shares in accordance with its Articles of Association.

Trading venue and investor considerations

The company’s proxy statement notes that its public shares trade on the OTC Markets Group Pink Open Market. It also cautions that there may not be sufficient liquidity in its securities at any given time and that shareholders may not be able to sell their public shares in the open market, even if the market price is lower than the redemption price available in connection with certain shareholder votes.

Overall, Healthcare AI Acquisition Corp. functions as a special purpose entity focused on completing an initial business combination within a defined timeframe, subject to shareholder approvals and extensions. Its SEC filings provide detailed information on its capital structure, trust account, redemption rights, sponsor arrangements, and the procedural steps required to complete or, if necessary, wind up its operations.